Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligo (Primer), Reagents), Type (Custom, Predesigned), Application (Therapeutic (ASO, siRNA), Research ((PCR, Sequencing, Diagnostics)), End User (Pharma, CROS, CMOs) - Global Forecast to 2027

November 2022 | 297 pages | ID: O0BB67C32D0EN
MarketsandMarkets

Abstracts

The global oligonucleotide synthesis market is projected to reach USD 16.7 billion by 2027 from USD 7.7 billion in 2022, at a CAGR of 16.8% during the forecast period. Market growth can be attributed to the increasing ongoing clinical trials for oligonucleotide-based therapies for leading therapeutic areas such as oncology.

“The primers segment will grow at the highest rate in the synthesized oligos market, by product”

By product, the synthesized oligonucleotides market segment is divided into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos such as BNA & LNA oligos. Primers are expected to show the highest growth over the forecast period owing to their wide applications in PCR, sequencing, gene synthesis, and cloning.

“By therapeutic application, the antisense oligonucleotide-based therapies segment accounted for the largest share of the oligonucleotide synthesis market in 2021”

The therapeutic application segment is further segmented into antisense oligonucleotide-based therapies, siRNA oligonucleotide-based therapies, and CpG oligonucleotide-based therapies. In 2021, antisense oligos accounted for the largest share of this segment as they form the basis of many therapies that are currently in clinical trials, thus boosting segment growth.

Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), Agilent Technologies, Inc. (US), Eurofins Scientific (Germany), Kaneka Corporation (Japan), Biolegio B.V. (Netherlands), Biolytic Lab Performance Inc. (US), Microsynth AG (Switzerland), ATDBio Ltd. (UK), Twist Bioscience Corporation (US), Eton Bioscience, Inc. (US), CSBIO (US), Tag Copenhagen A/S (Denmark), Biogen Inc. (US), Sarepta Therapeutics, Inc. (US), Ionis Pharmaceuticals, Inc. (US), and Alnylam Pharmaceuticals, Inc. (US) are some of the major players operating in the market.

“Asia Pacific region will register a highest CAGR in the oligonucleotide synthesis market”

The market for oligonucleotide synthesis in Asia Pacific is anticipated to develop at the fastest rate during the forecast period. Growing R&D funding and research activity, increased product availability and decreased outsourcing costs are some of the factors that are likely to propel market growth.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side - 20%
• By Designation: Managers- 45%, CXOs, and Director level - 30%, and Executives - 25%
• By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%

List of Companies Profiled in the Report:

• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• Danaher Corporation (US)
• LGC Limited (UK)
• Maravai Life Sciences (US)
• Agilent Technologies, Inc. (US)
• Eurofins Scientific (Germany)
• Kaneka Corporation (Japan)
• Biolegio B.V. (Netherlands)
• Biolytic Lab Performance Inc. (US)
• Microsynth AG (Switzerland)
• ATDBio Ltd. (UK)
• Twist Bioscience Corporation (US)
• Eton Bioscience, Inc. (US)
• CSBIO (US)
• Tag Copenhagen A/S (Denmark)
• Generi Biotech (Czech Republic)
• Biocomma Limited (China)
• Hongene Biotech Corporation (China)
• Hangzhou pharm &chem Co., Ltd (China)
• Tokyo Chemical Industry Co., Ltd. (Japan)
• Biogen Inc. (US)
• Sarepta Therapeutics, Inc. (US)
• Ionis Pharmaceuticals, Inc. (US)
• Alnylam Pharmaceuticals, Inc. (US)

Research Coverage:

This report provides a detailed picture of the oligonucleotide synthesis market. It aims to estimate the market’s size and future growth potential across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players and their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

Contents

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
  1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
  1.3.1 MARKETS COVERED
  1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
  2.1.1 SECONDARY DATA
  2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (RESEARCH AND DIAGNOSTIC MARKET)
FIGURE 4 MARKET SIZE ESTIMATION- COMPANY REVENUE ANALYSIS-BASED ESTIMATION (THERAPEUTIC MARKET)
FIGURE 5 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE (USD MILLION)
FIGURE 6 OLIGONUCLEOTIDE SYNTHESIS MARKET: FINAL CAGR PROJECTIONS (2022?2027)
FIGURE 7 OLIGONUCLEOTIDE SYNTHES MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 8 OLIGONUCLEOTIDE SYNTHESIS: SEGMENTAL ASSESSMENT
  2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 9 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.4 STUDY ASSUMPTIONS
2.5 RISK ANALYSIS

3 EXECUTIVE SUMMARY

FIGURE 11 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 12 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 13 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF OLIGONUCLEOTIDE SYNTHESIS MARKET

4 PREMIUM INSIGHTS

4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW
FIGURE 15 INCREASING USE OF SYNTHETIC OLIGOS TO DRIVE MARKET
4.2 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION AND COUNTRY (2021)
FIGURE 16 THERAPEUTIC APPLICATION SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021
4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY PRODUCT, 2022 VS. 2027
FIGURE 17 OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO DOMINATE MARKET IN 2027
4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION, 2022
FIGURE 18 THERAPEUTIC APPLICATION SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2022
4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 ASIA PACIFIC COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  5.2.1 DRIVERS
    5.2.1.1 Increasing use of synthesized oligos in therapeutic applications
TABLE 1 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES
FIGURE 21 ONGOING CLINICAL TRIALS BY TOP 10 THERAPEUTIC AREAS
    5.2.1.2 Increasing government investments in synthetic biology and genome projects
    5.2.1.3 Growing focus on personalized medicine
  5.2.2 RESTRAINTS
    5.2.2.1 Complexities associated with therapeutic oligos
  5.2.3 OPPORTUNITIES
    5.2.3.1 Increasing R&D investments by key players in emerging economies
  5.2.4 CHALLENGES
    5.2.4.1 Delivery of oligonucleotide drugs to specific targets
5.3 RANGES/SCENARIOS
FIGURE 22 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF OLIGONUCLEOTIDE SYNTHESIS MARKET
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 24 DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
  5.5.1 KEY INFLUENCERS
5.6 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
5.7 ECOSYSTEM ANALYSIS
FIGURE 26 ECOSYSTEM ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET
  5.7.1 ROLE IN ECOSYSTEM
5.8 TECHNOLOGICAL ANALYSIS
  5.8.1 SOLID-PHASE SYNTHESIS
  5.8.2 LIQUID-PHASE SYNTHESIS
5.9 INDICATIVE PRICING MODEL ANALYSIS
TABLE 2 PRICING ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
5.10 TRADE DATA
TABLE 3 IMPORT DATA FOR OLIGONUCLEOTIDES, BY COUNTRY, 2016–2020 (USD THOUSAND)
5.11 REGULATORY ANALYSIS
  5.11.1 GOVERNMENT REGULATIONS FOR OLIGONUCLEOTIDE-BASED DRUGS
  5.11.2 GOVERNMENT REGULATIONS FOR OLIGONUCLEOTIDE-BASED DRUGS: GOOD MANUFACTURING PRACTICES (GMP)
  5.11.3 ISO 13485
  5.11.4 IVD & ASR
5.12 PATENT ANALYSIS
FIGURE 27 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS (JANUARY 2012–OCTOBER 2022)
TABLE 4 INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
5.13 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 PORTER’S FIVE FORCES ANALYSIS
  5.13.1 DEGREE OF COMPETITION
  5.13.2 BARGAINING POWER OF SUPPLIERS
  5.13.3 BARGAINING POWER OF BUYERS
  5.13.4 THREAT OF SUBSTITUTES
  5.13.5 THREAT OF NEW ENTRANTS
5.14 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 6 OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES AND EVENTS
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
5.16 KEY BUYING CRITERIA BY END USERS
FIGURE 29 BUYING CRITERIA OF END USERS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS

6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT

6.1 INTRODUCTION
TABLE 7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 8 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY REGION, 2020–2027 (USD MILLION)
TABLE 9 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 10 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 11 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 12 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION)
6.2 OLIGONUCLEOTIDE-BASED DRUGS
  6.2.1 OLIGONUCLEOTIDE-BASED DRUGS DOMINATED MARKET IN 2021
TABLE 13 OLIGONUCLEOTIDE-BASED THERAPIES
TABLE 14 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2020–2027 (USD MILLION)
TABLE 15 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 16 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 17 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 18 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 SYNTHESIZED OLIGONUCLEOTIDES
TABLE 19 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
TABLE 20 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 21 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 22 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 23 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
  6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT
TABLE 24 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
    6.3.1.1 Primers
      6.3.1.1.1 Increasing applications for oligo primers in DNA sequencing and molecular diagnostics to drive segment
TABLE 25 PRIMERS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
TABLE 26 PRIMERS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 27 PRIMERS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 PRIMERS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 29 PRIMERS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3.1.2 Probes
      6.3.1.2.1 Probes to detect various infectious agents and altered DNA/RNA sequences
TABLE 30 PROBES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
TABLE 31 PROBES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 32 PROBES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 33 PROBES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 34 PROBES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3.1.3 DNA oligos
      6.3.1.3.1 Innovations in DNA oligos to eliminate time-consuming PCR and drive segment
TABLE 35 DNA OLIGOS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
TABLE 36 DNA OLIGOS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 37 DNA OLIGOS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 38 DNA OLIGOS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 39 DNA OLIGOS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3.1.4 RNA oligos
      6.3.1.4.1 RNA oligos to be used as molecular diagnostic tools
TABLE 40 RNA OLIGOS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
TABLE 41 RNA OLIGOS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 42 RNA OLIGOS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 43 RNA OLIGOS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 44 RNA OLIGOS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3.1.5 Other synthesized oligonucleotides
TABLE 45 OTHER SYNTHESIZED OLIGONUCLEOTIDES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
TABLE 46 OTHER SYNTHESIZED OLIGONUCLEOTIDES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 47 OTHER SYNTHESIZED OLIGONUCLEOTIDES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 OTHER SYNTHESIZED OLIGONUCLEOTIDES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 OTHER SYNTHESIZED OLIGONUCLEOTIDES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
  6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
TABLE 50 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
    6.3.2.1 Custom oligonucleotides
      6.3.2.1.1 Surge in demand in clinical and preclinical studies to propel segment
TABLE 51 CUSTOM OLIGONUCLEOTIDES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
TABLE 52 CUSTOM OLIGONUCLEOTIDES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 CUSTOM OLIGONUCLEOTIDES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 CUSTOM OLIGONUCLEOTIDES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 55 CUSTOM OLIGONUCLEOTIDES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3.2.2 Predesigned oligos
      6.3.2.2.1 Predesigned oligos to be used in routine research applications, such as PCR and sequencing
TABLE 56 PREDESIGNED OLIGOS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
TABLE 57 PREDESIGNED OLIGOS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 58 PREDESIGNED OLIGOS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 59 PREDESIGNED OLIGOS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 60 PREDESIGNED OLIGOS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 REAGENTS
  6.4.1 GROWING APPLICATIONS OF OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO PROPEL MARKET
TABLE 61 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 62 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 63 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 64 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 65 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 EQUIPMENT
  6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO STIMULATE MARKET
TABLE 66 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY REGION, 2020–2027 (USD MILLION)
TABLE 67 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 68 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 69 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 70 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)

7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION

7.1 INTRODUCTION
TABLE 71 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 72 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 73 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY REGION, 2020–2027 (USD MILLION)
TABLE 74 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 75 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 76 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 77 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION)
7.2 THERAPEUTIC APPLICATIONS
TABLE 78 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 79 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 80 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 81 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 82 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
  7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY TYPE
TABLE 83 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
    7.2.1.1 Antisense oligonucleotide-based therapies
      7.2.1.1.1 Antisense oligos to form basis of therapies in clinical trials
TABLE 84 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 85 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 86 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 87 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 88 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.2.1.2 siRNA oligonucleotide-based therapies
      7.2.1.2.1 Ease of drug target identification with bioinformatics to boost segment
TABLE 89 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 90 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 91 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 92 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 93 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.2.1.3 CpG oligonucleotide-based therapies
      7.2.1.3.1 CpG ODNs to show significant potential for variety of disease treatments, including cancer
TABLE 94 CPG OLIGONUCLEOTIDE-BASED THERAPIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 95 CPG OLIGONUCLEOTIDE-BASED THERAPIES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 96 CPG OLIGONUCLEOTIDE-BASED THERAPIES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 97 CPG OLIGONUCLEOTIDE-BASED THERAPIES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 98 CPG OLIGONUCLEOTIDE-BASED THERAPIES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
  7.2.2 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
TABLE 99 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
    7.2.2.1 Neurological disorders
      7.2.2.1.1 Neurological disorders dominated market by disease type in 2020
TABLE 100 NEUROLOGICAL DISORDERS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 101 NEUROLOGICAL DISORDERS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 102 NEUROLOGICAL DISORDERS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 103 NEUROLOGICAL DISORDERS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 104 NEUROLOGICAL DISORDERS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.2.2.2 Infectious diseases
      7.2.2.2.1 Antisense therapies and oligonucleotide aptamers to be significant in treatment and diagnosis of infectious diseases
TABLE 105 INFECTIOUS DISEASES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 106 INFECTIOUS DISEASES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 107 INFECTIOUS DISEASES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 108 INFECTIOUS DISEASES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 109 INFECTIOUS DISEASES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.2.2.3 Other diseases
TABLE 110 OTHER DISEASES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 111 OTHER DISEASES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 112 OTHER DISEASES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 113 OTHER DISEASES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 114 OTHER DISEASES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 RESEARCH APPLICATIONS
TABLE 115 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 116 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 117 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 118 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 119 ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 120 LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
  7.3.1 PCR
    7.3.1.1 Increasing use of PCR in research to drive market
TABLE 121 PCR: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 122 PCR: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 123 PCR: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 124 PCR: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 125 PCR: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
  7.3.2 SEQUENCING
    7.3.2.1 Advancements in technologies and low cost of DNA sequencing to boost segment
TABLE 126 SEQUENCING: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 127 SEQUENCING: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 128 SEQUENCING: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 129 SEQUENCING: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 130 SEQUENCING: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
  7.3.3 OTHER RESEARCH APPLICATIONS
TABLE 131 OTHER RESEARCH APPLICATIONS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 132 OTHER RESEARCH APPLICATIONS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 133 OTHER RESEARCH APPLICATIONS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 134 OTHER RESEARCH APPLICATIONS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 135 OTHER RESEARCH APPLICATIONS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 DIAGNOSTIC APPLICATIONS
  7.4.1 GROWING FIELDS OF MOLECULAR DIAGNOSTICS (MDX) AND IN VITRO DIAGNOSTICS (IVD) TO AUGMENT SEGMENT
TABLE 136 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 137 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 138 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 139 ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 140 LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER

8.1 INTRODUCTION
TABLE 141 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 142 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY REGION, 2020–2027 (USD MILLION)
TABLE 143 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 144 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 145 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 146 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION)
8.2 HOSPITALS
  8.2.1 INCREASING FDA-APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS TO STIMULATE MARKET
TABLE 147 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION)
TABLE 148 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 149 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 151 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY AND THERAPEUTICS TO DRIVE SEGMENT
TABLE 152 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 153 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 154 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 155 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 156 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 DIAGNOSTIC LABORATORIES
  8.4.1 INCREASING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO STIMULATE GROWTH
TABLE 157 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 158 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 159 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 160 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 161 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS
  8.5.1 WIDE RANGE OF CUSTOMIZED OLIGO SERVICES TO AID GROWTH
TABLE 162 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2020–2027 (USD MILLION)
TABLE 163 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 164 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 165 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 166 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION)
8.6 ACADEMIC RESEARCH & INSTITUTES
  8.6.1 ACADEMIC AND GOVERNMENT RESEARCHERS TO USE OLIGOS FOR GENOMIC TECHNOLOGIES
TABLE 167 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
TABLE 168 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 169 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 170 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 171 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)

9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION

9.1 INTRODUCTION
TABLE 172 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2020–2027 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 30 NORTH AMERICA: MARKET SNAPSHOT
TABLE 173 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 174 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 175 NORTH AMERICA: SYNTHESIZES OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 176 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDE SYNTHESIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 177 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 178 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 179 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 180 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 181 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
  9.2.1 US
    9.2.1.1 Government initiatives and strategic developments to drive market
TABLE 182 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 183 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 184 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 185 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 186 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 187 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 188 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 189 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
  9.2.2 CANADA
    9.2.2.1 Strong research infrastructure and availability of funding to support market
TABLE 190 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 191 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 192 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 193 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 194 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 195 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 196 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 197 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3 EUROPE
TABLE 198 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 199 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 200 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 201 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 202 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 203 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 204 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 205 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 206 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
  9.3.1 UK
    9.3.1.1 Increasing strategic developments by market players to propel market
TABLE 207 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 208 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 209 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 210 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 211 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 212 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 213 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 214 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
  9.3.2 GERMANY
    9.3.2.1 Presence of several academic & research institutes to aid growth
TABLE 215 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 216 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 217 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 218 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 219 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 220 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 221 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 222 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
  9.3.3 FRANCE
    9.3.3.1 Government initiatives to strengthen R&D activities and drive market
TABLE 223 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 224 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 225 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 226 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 227 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 228 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 229 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 230 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
  9.3.4 ITALY
    9.3.4.1 Increasing research activities in life sciences to boost market
TABLE 231 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 232 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 233 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 234 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 235 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 236 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 237 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 238 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
  9.3.5 SPAIN
    9.3.5.1 Government initiatives for development of biomedicine and healthcare sectors to stimulate market
TABLE 239 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 240 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 241 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 242 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 243 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 244 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 245 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 246 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
  9.3.6 REST OF EUROPE
TABLE 247 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 248 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 249 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 250 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 251 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 252 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 253 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 254 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: MARKET SNAPSHOT
TABLE 255 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 256 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 257 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 258 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 259 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 260 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 261 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 262 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 263 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
  9.4.1 CHINA
    9.4.1.1 Increasing focus of Chinese biopharma companies to aid market
TABLE 264 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 265 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 266 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 267 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 268 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 269 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 270 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 271 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
  9.4.2 JAPAN
    9.4.2.1 Increasing awareness of oligos through conferences and workshops to drive market
TABLE 272 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 273 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 274 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 275 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 276 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 277 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 278 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 279 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
  9.4.3 INDIA
    9.4.3.1 Strong initiatives to develop bio clusters and increased adoption of genomic technologies to aid market
TABLE 280 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 281 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 282 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 283 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 284 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 285 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 286 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 287 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
  9.4.4 REST OF ASIA PACIFIC
TABLE 288 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 289 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 290 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 291 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 292 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 293 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 294 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 295 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
9.5 LATIN AMERICA
TABLE 296 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 297 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 298 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 299 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 300 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 301 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 302 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 303 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 304 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
  9.5.1 BRAZIL
    9.5.1.1 Growing prevalence of infectious and non-infectious diseases to support market
TABLE 305 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 306 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 307 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 308 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 309 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 310 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 311 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 312 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
  9.5.2 MEXICO
    9.5.2.1 Increasing research in synthetic biology to drive market
TABLE 313 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 314 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 315 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 316 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 317 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 318 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 319 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 320 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
  9.5.3 REST OF LATIN AMERICA
TABLE 321 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 322 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 323 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 324 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 325 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 326 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 327 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 328 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
  9.6.1 GROWING ACCEPTANCE OF PERSONALIZED MEDICINE TO PROPEL MARKET
TABLE 329 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 330 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 331 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 332 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 333 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 334 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 335 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 336 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
TABLE 337 OLIGONUCLEOTIDE SYNTHESIS MARKET: KEY STRATEGIES ADOPTED
10.3 MARKET SHARE ANALYSIS
FIGURE 32 OLIGONUCLEOTIDE SYNTHESIS MARKET: MARKET SHARE ANALYSIS (RESEARCH AND DIAGNOSTIC MARKET), 2021
TABLE 338 OLIGONUCLEOTIDE SYNTHESIS MARKET (FOR RESEARCH AND DIAGNOSTIC MARKET): DEGREE OF COMPETITION
FIGURE 33 OLIGONUCLEOTIDE SYNTHESIS MARKET: MARKET SHARE ANALYSIS (THERAPEUTIC MARKET), 2021
TABLE 339 OLIGONUCLEOTIDE SYNTHESIS MARKET (FOR THERAPEUTICS MARKET): DEGREE OF COMPETITION
10.4 REVENUE ANALYSIS: OLIGONUCLEOTIDE SYNTHESIS MARKET
FIGURE 34 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021)
10.5 COMPANY EVALUATION MATRIX
FIGURE 35 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX, 2021
  10.5.1 STARS
  10.5.2 EMERGING LEADERS
  10.5.3 PERVASIVE PLAYERS
  10.5.4 PARTICIPANTS
10.6 COMPANY EVALUATION MATRIX: START-UPS/SMES
FIGURE 36 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
  10.6.1 PROGRESSIVE COMPANIES
  10.6.2 STARTING BLOCKS
  10.6.3 RESPONSIVE COMPANIES
  10.6.4 DYNAMIC COMPANIES
10.7 COMPETITIVE BENCHMARKING OF START-UPS/SMES
TABLE 340 OLIGONUCLEOTIDE SYNTHESIS MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 341 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES
10.8 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
  10.8.1 COMPANY FOOTPRINT
TABLE 342 COMPANY FOOTPRINT ANALYSIS: KEY PLAYERS
  10.8.2 PRODUCT FOOTPRINT
TABLE 343 PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS
  10.8.3 APPLICATION FOOTPRINT
TABLE 344 APPLICATION FOOTPRINT ANALYSIS: KEY PLAYERS
  10.8.4 REGIONAL FOOTPRINT
TABLE 345 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS
10.9 COMPETITIVE SCENARIO AND TRENDS
  10.9.1 PRODUCT LAUNCHES
TABLE 346 OLIGONUCLEOTIDE SYNTHESIS MARKET: PRODUCT LAUNCHES (JANUARY 2019–OCTOBER 2022)
  10.9.2 DEALS
TABLE 347 OLIGONUCLEOTIDE SYNTHESIS MARKET: DEALS (JANUARY 2019–OCTOBER 2022)
  10.9.3 OTHER DEVELOPMENTS
TABLE 348 OLIGONUCLEOTIDE SYNTHESIS MARKET: OTHER DEVELOPMENTS (JANUARY 2019–OCTOBER 2022)

11 COMPANY PROFILES

11.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, Recent Developments, and MnM View)*
  11.1.1 DANAHER CORPORATION
TABLE 349 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT
  11.1.2 THERMO FISHER SCIENTIFIC INC.
TABLE 350 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  11.1.3 MERCK KGAA
TABLE 351 MERCK KGAA: COMPANY OVERVIEW
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT
  11.1.4 EUROFINS SCIENTIFIC
TABLE 352 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
FIGURE 40 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
  11.1.5 LGC LIMITED
TABLE 353 LGC LIMITED: COMPANY OVERVIEW
FIGURE 41 LGC LIMITED: COMPANY SNAPSHOT
  11.1.6 AGILENT TECHNOLOGIES, INC.
TABLE 354 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  11.1.7 KANEKA CORPORATION
TABLE 355 KANEKA CORPORATION: COMPANY OVERVIEW
FIGURE 43 KANEKA CORPORATION: COMPANY SNAPSHOT
  11.1.8 MARAVAI LIFESCIENCES
TABLE 356 MARAVAI LIFESCIENCES: COMPANY OVERVIEW
FIGURE 44 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT
  11.1.9 BIOLEGIO B.V.
TABLE 357 BIOLEGIO B.V.: COMPANY OVERVIEW
  11.1.10 BIOLYTIC LAB PERFORMANCE INC.
TABLE 358 BIOLYTIC LAB PERFORMANCE INC.: COMPANY OVERVIEW
  11.1.11 MICROSYNTH AG
TABLE 359 MICROSYNTH AG: COMPANY OVERVIEW
11.2 THERAPEUTIC PLAYERS
  11.2.1 BIOGEN INC.
TABLE 360 BIOGEN INC.: COMPANY OVERVIEW
FIGURE 45 BIOGEN INC.: COMPANY SNAPSHOT
  11.2.2 SAREPTA THERAPEUTICS, INC.
TABLE 361 SAREPTA THERAPEUTICS INC.: COMPANY OVERVIEW
FIGURE 46 SAREPTA THERAPEUTICS INC.: COMPANY SNAPSHOT
  11.2.3 IONIS PHARMACEUTICALS, INC.
TABLE 362 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
FIGURE 47 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  11.2.4 ALNYLAM PHARMACEUTICALS, INC.
TABLE 363 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
FIGURE 48 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
* Business Overview, Products/Services/Solutions Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
11.3 OTHER PLAYERS
  11.3.1 ADTBIO LTD.
  11.3.2 TWIST BIOSCIENCE CORPORATION
  11.3.3 ETON BIOSCIENCE, INC.
  11.3.4 CSBIO
  11.3.5 TAG COPENHAGEN A/S
  11.3.6 GENERI BIOTECH
  11.3.7 BIOCOMMA LIMITED
  11.3.8 HONGENE BIOTECH CORPORATION
  11.3.9 HANGZHOU PHARM &CHEM CO., LTD.
  11.3.10 TOKYO CHEMICAL INDUSTRY CO., LTD. (TCI)

12 APPENDIX

12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS

About

In the coming five years, growth in the oligonucleotide synthesis market is likely to be centered on China, Malaysia, Singapore, and India. This can be attributed to the growing availability of synthesized oligos along with an increase in the R&D funding and activities in the APAC region. Furthermore, increasing focus of prominent players in the APAC market is another factor driving the growth of this market. For instance, in July 2013, Integrated DNA Technologies, Inc. (IDT) opened an oligonucleotides manufacturing facility in Singapore to cater to the research companies in the APAC region, thereby establishing its footprint in the APAC market. Such developments are likely to spur the growth of the APAC oligonucleotide synthesis market in the coming years.

The key strategies followed by most companies in the oligonucleotide synthesis market are new product launches; agreements, collaborations, and partnerships; mergers and acquisitions; and expansions. Of all the growth strategies adopted by players in this field, agreements, collaborations, and partnerships accounted for the largest share of XX% of the overall growth strategies from 2010 to 2014. Some leading players adopting these strategies are BioAutomation Corporation (U.S.), Eurofins Genomics (Germany), and GE Healthcare (U.K.). Expansions accounted for the second-largest share of XX% of the overall growth strategies adopted by the players in the market.

The prominent players in the oligonucleotide synthesis market are Agilent Technologies, Inc. (U.S.), BioAutomation Corporation (U.S.), BioSearch Technologies, Inc. (U.S.), Eurofins Genomics (Germany), Eurogentec (Belgium), GE Healthcare (U.K.), Glen Research (U.S.), Gene Link, Inc. (U.S.), GenScript USA Inc. (U.S.), GeneDesign, Inc. (Japan), Integrated DNA Technologies, Inc. (IDT) (U.S.), Link Technologies, Ltd. (U.K.), Nitto Denko Avecia, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and TriLink BioTechnologies, Inc. (U.S.).

North America commands the largest share of the global oligonucleotide synthesis market, followed by Europe. However, the European oligonucleotide synthesis market is expected to grow at a slower pace as compared to North America due to the Eurozone debt crisis. The Asia-Pacific market, on the other hand, is in the growth phase and is the fastest-growing region in the global oligonucleotide synthesis market. The growth in the APAC oligonucleotide synthesis market is likely to be centered at China, Malaysia, Singapore, and India. This can be attributed to the growing availability of synthesized oligos and the increase in R&D funding and activities in the APAC region. Furthermore, increasing focus of prominent players on the APAC region is another factor driving the growth of this market.

Oligonucleotide synthesis is a highly commoditized market. With its rising attractiveness, an increasing number of companies are moving into this niche market, resulting in price pressure. Oligos have been branded as relatively more expensive research tools as compared to other life sciences research tools. This is further restricting the industry growth, as there are certain limitations related to increasing the cost of oligos. This factor is making it difficult for market players to survive and/or grow at a faster and desired pace. However, market consolidation in the coming years can bring price enhancement in this industry.

The importance of synthetic oligonucleotides as therapeutic drugs for treating diseases has grown significantly over the last decade. Some of the major driving factors for this growth are characterization of more targets following the identification of the human genome, advancements in antisense oligonucleotides, and the development of double stranded small interfering RNA (siRNA). Therapeutic oligos can either be single stranded such as antisense oligonucleotides or double stranded such as siRNA. Furthermore, therapeutic oligos can be useful in treating diseases ranging from viral infections, respiratory diseases, and cancer to rare diseases such as Duchenne Muscular Dystrophy (DMD), Cystic Fibrosis, and Thrombic Thrombocytopenic Purpura.

Currently, only two oligonucleotide-based drugs, namely, Vitravene and Macugen have received market approval and a large number of oligonucleotide-based drugs are in various stages of clinical development in the U.S., Canada, Europe, and other parts of the world. As of 2011, there were over XX oligonucleotide-based drugs in clinical development in the U.S., Europe, and Canada; some of these include antisense oligonucleotides, immunostimulatory oligonucleotides, DNA duplex decoys, siRNAs, ribozymes, microRNAs, aptamers, and spiegelmers. Although most oligonucleotides in clinical development are chemically similar, the mechanisms of their action vary widely. As a result, the development of a unified set of regulatory guidelines that can effectively address the safety and quality requirements for such a diverse group of molecular entities with various unique mechanisms of action is a challenging task.

There are no formal regulatory guidelines available from any regulatory agency for the development of this class of therapeutics. It has been a general practice for regulatory agencies to apply guidelines proposed for small molecules to oligonucleotide therapeutics, owing to their similar characteristics. These include all quality-related regulatory guidelines issued by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Thus, there is a need to address the basic regulatory issues regarding the chemistry, manufacturing, and control of drugs and products belonging to this unique class of therapeutics.